Trial result ·
Time to viral load suppression with 8-week versus 12-week ravidasvir/sofosbuvir regimens among chronic hepatitis C patients in Malaysia: a non-inferiority, randomized clinical trial.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This study looked at people with long-term hepatitis C in Malaysia. All took a drug mix of ravidasvir and sofosbuvir. People were randomly put into groups for 8 weeks or 12 weeks. The trial ran at many centers from 2016 to 2020. It had 321 adults, and everyone knew which group they were in. This report took a fresh look at the trial data. It asked how fast the virus level fell below a set limit.
What they found
In both groups, the typical time to reach that limit was 28 days. A simple comparison showed no clear gap between the groups. A fuller analysis that took other factors into account gave a different view. In it, the 8-week group was more likely to reach the limit sooner. People with more virus at the start took longer to get there. Other personal and health factors did not make a clear difference.
What it means for patients
The authors say both treatment lengths brought the virus down fast. They say the 8-week course could be a good choice for genotype 1. Most people in this trial had genotype 3 hepatitis C. For them, the authors say more study is needed first.
Why it is not certain yet
The authors say the study had limited power to find true gaps. So the earlier result for the 8-week course needs care. The effect of treatment length seemed to differ by virus genotype. This is a second look at old trial data, not a new trial. The abstract does not report side effects or long-term outcomes.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Time to viral load suppression with 8-week versus 12-week ravidasvir/sofosbuvir regimens among chronic hepatitis C patients in Malaysia: a non-inferiority, randomized clinical trial.
PubMed · PMID 42277657We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Hepatitis C publications